INMODE LTD (INMD) Stock Fundamental Analysis
NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD
INMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INMD is valued quite cheap, while showing a decent growth score. This is a good combination! This makes INMD very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year INMD was profitable.
INMD had a positive operating cash flow in the past year.
INMD had positive earnings in each of the past 5 years.
In the past 5 years INMD always reported a positive cash flow from operatings.
1.2 Ratios
INMD has a better Return On Assets (24.94%) than 98.40% of its industry peers.
INMD has a Return On Equity of 28.38%. This is amongst the best in the industry. INMD outperforms 97.86% of its industry peers.
With an excellent Return On Invested Capital value of 15.86%, INMD belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for INMD is significantly above the industry average of 7.89%.
The last Return On Invested Capital (15.86%) for INMD is well below the 3 year average (22.89%), which needs to be investigated, but indicates that INMD had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.94% | ||
| ROE | 28.38% | ||
| ROIC | 15.86% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
1.3 Margins
The Profit Margin of INMD (44.80%) is better than 98.40% of its industry peers.
In the last couple of years the Profit Margin of INMD has grown nicely.
INMD has a better Operating Margin (28.05%) than 96.79% of its industry peers.
INMD's Operating Margin has declined in the last couple of years.
The Gross Margin of INMD (80.03%) is better than 93.58% of its industry peers.
In the last couple of years the Gross Margin of INMD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.05% | ||
| PM (TTM) | 44.8% | ||
| GM | 80.03% |
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
2. Health
2.1 Basic Checks
INMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for INMD has been reduced compared to 1 year ago.
INMD has more shares outstanding than it did 5 years ago.
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.75
WACC9.07%
2.3 Liquidity
A Current Ratio of 8.73 indicates that INMD has no problem at all paying its short term obligations.
INMD has a better Current ratio (8.73) than 89.84% of its industry peers.
A Quick Ratio of 7.86 indicates that INMD has no problem at all paying its short term obligations.
INMD has a Quick ratio of 7.86. This is amongst the best in the industry. INMD outperforms 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.73 | ||
| Quick Ratio | 7.86 |
3. Growth
3.1 Past
INMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.04%.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
INMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.76%.
Measured over the past years, INMD shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
3.2 Future
INMD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.28% yearly.
The Revenue is expected to grow by 2.63% on average over the next years.
EPS Next Y-3.16%
EPS Next 2Y3.68%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue Next Year-5.17%
Revenue Next 2Y-0.02%
Revenue Next 3Y2.63%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.31, which indicates a rather cheap valuation of INMD.
Based on the Price/Earnings ratio, INMD is valued cheaply inside the industry as 97.33% of the companies are valued more expensively.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.61.
INMD is valuated cheaply with a Price/Forward Earnings ratio of 7.26.
INMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. INMD is cheaper than 97.33% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of INMD to the average of the S&P500 Index (37.13), we can say INMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.31 | ||
| Fwd PE | 7.26 |
4.2 Price Multiples
INMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INMD is cheaper than 99.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, INMD is valued cheaply inside the industry as 98.40% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.2 | ||
| EV/EBITDA | 1.27 |
4.3 Compensation for Growth
INMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.32
EPS Next 2Y3.68%
EPS Next 3Y6.28%
5. Dividend
5.1 Amount
No dividends for INMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INMD (7/31/2025, 9:39:50 AM)
13.89
-0.01 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners72.46%
Inst Owner Change-0.52%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap877.99M
Analysts72.31
Price Target17.39 (25.2%)
Short Float %6.18%
Short Ratio2.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.98%
Min EPS beat(2)-20.27%
Max EPS beat(2)-13.69%
EPS beat(4)1
Avg EPS beat(4)-9.56%
Min EPS beat(4)-20.27%
Max EPS beat(4)8.88%
EPS beat(8)3
Avg EPS beat(8)-6.75%
EPS beat(12)7
Avg EPS beat(12)-0.58%
EPS beat(16)11
Avg EPS beat(16)2.13%
Revenue beat(2)0
Avg Revenue beat(2)-6.17%
Min Revenue beat(2)-9.96%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-16.64%
Max Revenue beat(4)0.53%
Revenue beat(8)2
Avg Revenue beat(8)-6.51%
Revenue beat(12)6
Avg Revenue beat(12)-2.94%
Revenue beat(16)10
Avg Revenue beat(16)-0.79%
PT rev (1m)0%
PT rev (3m)-19.45%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)-14.62%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-12.28%
Revenue NQ rev (1m)-1.48%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.31 | ||
| Fwd PE | 7.26 | ||
| P/S | 2.24 | ||
| P/FCF | 7.2 | ||
| P/OCF | 7.16 | ||
| P/B | 1.42 | ||
| P/tB | 1.42 | ||
| EV/EBITDA | 1.27 |
EPS(TTM)1.9
EY13.68%
EPS(NY)1.91
Fwd EY13.77%
FCF(TTM)1.93
FCFY13.89%
OCF(TTM)1.94
OCFY13.96%
SpS6.21
BVpS9.8
TBVpS9.8
PEG (NY)N/A
PEG (5Y)0.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.94% | ||
| ROE | 28.38% | ||
| ROCE | 17.41% | ||
| ROIC | 15.86% | ||
| ROICexc | 84.14% | ||
| ROICexgc | 84.14% | ||
| OM | 28.05% | ||
| PM (TTM) | 44.8% | ||
| GM | 80.03% | ||
| FCFM | 31.08% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score6
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 87.11% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.65% | ||
| Profit Quality | 69.38% | ||
| Current Ratio | 8.73 | ||
| Quick Ratio | 7.86 | ||
| Altman-Z | N/A |
F-Score6
WACC9.07%
ROIC/WACC1.75
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-3.16%
EPS Next 2Y3.68%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-5.17%
Revenue Next 2Y-0.02%
Revenue Next 3Y2.63%
Revenue Next 5YN/A
EBIT growth 1Y-36.29%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-31.82%
EBIT Next 3Y-5%
EBIT Next 5YN/A
FCF growth 1Y-27.92%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-28.22%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%